This trial is active, not recruiting.

Condition breast cancer
Sponsor University of Vermont
Collaborator American Cancer Society, Inc.
Start date August 2009
End date October 2010
Trial size 60 participants
Trial identifier NCT01341171, V0805


Single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.

United States No locations recruiting
Other countries No locations recruiting

Primary Outcomes

Angiogenic Protein levels
time frame: following 6 months of therapy

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - women routinely taking tamoxifen or aromatase inhibitor therapy as prescribed by their oncologist Exclusion Criteria: - Use of heparin, warfarin

Additional Information

Official title Platelet Modulation in the Control of Angiogenesis: The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Activation and Angiogenic Proteins
Principal investigator Chris E Holmes, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in April 2011.
Information provided to ClinicalTrials.gov by University of Vermont.